Conroy T, Ducreux M
Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Université de Lorraine, INSERM INSPIIRE, Nancy, France.
INSERM U1279, Université Paris-Saclay, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
ESMO Open. 2025 Apr;10(4):104528. doi: 10.1016/j.esmoop.2025.104528. Epub 2025 Apr 9.
• This ESMO Clinical Practice Guideline Express Update addresses developments in the management of metastatic pancreatic cancer. • It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen). • Updated first- and second-line treatment recommendations are provided. • An updated management algorithm for metastatic pancreatic cancer is also included.
• 本欧洲肿瘤内科学会(ESMO)临床实践指南快速更新涉及转移性胰腺癌管理方面的进展。
• 它是在一线纳米脂质体伊立替康(NALIRIFOX方案)获批后发布的。
• 提供了更新的一线和二线治疗建议。
• 还纳入了转移性胰腺癌的更新管理算法。